These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 21361734)

  • 21. Change in cytokine levels after administration of saikokaryuukotsuboreito or testosterone in patients with symptoms of late-onset hypogonadism.
    Tsujimura A; Miyagawa Y; Okuda H; Yamamoto K; Fukuhara S; Nakayama J; Takao T; Nonomura N; Okuyama A
    Aging Male; 2011 Mar; 14(1):76-81. PubMed ID: 20712429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women.
    Goldstat R; Briganti E; Tran J; Wolfe R; Davis SR
    Menopause; 2003; 10(5):390-8. PubMed ID: 14501599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new testosterone gel (fortesta) for hypogonadism.
    Med Lett Drugs Ther; 2011 Apr; 53(1362):29-30. PubMed ID: 21502933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absorption of testosterone gel 1% (Testim) from three different application sites.
    Guay AT; Smith TM; Offutt LA
    J Sex Med; 2009 Sep; 6(9):2601-10. PubMed ID: 19549089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum Testosterone (T) Level Variability in T Gel-Treated Older Hypogonadal Men: Treatment Monitoring Implications.
    Swerdloff RS; Pak Y; Wang C; Liu PY; Bhasin S; Gill TM; Matsumoto AM; Pahor M; Surampudi P; Snyder PJ
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3280-7. PubMed ID: 26120790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association of time of day and serum testosterone concentration in a large screening population.
    Crawford ED; Barqawi AB; O'Donnell C; Morgentaler A
    BJU Int; 2007 Sep; 100(3):509-13. PubMed ID: 17555474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia.
    Dobs AS; Schrott H; Davidson MH; Bays H; Stein EA; Kush D; Wu M; Mitchel Y; Illingworth RD
    Metabolism; 2000 Sep; 49(9):1234-8. PubMed ID: 11016911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
    Moisey R; Swinburne J; Orme S
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.
    Swerdloff RS; Wang C
    Aging Male; 2003 Sep; 6(3):207-11. PubMed ID: 14628501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transfer of transdermally applied testosterone to clothing: a comparison of a testosterone patch versus a testosterone gel.
    Mazer N; Fisher D; Fischer J; Cosgrove M; Bell D; Eilers B
    J Sex Med; 2005 Mar; 2(2):227-34. PubMed ID: 16422890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spuriously elevated testosterone measurements caused by application of testosterone gel at or near the phlebotomy site.
    Kirk D; Misita C
    Ann Pharmacother; 2013 Jan; 47(1):e5. PubMed ID: 23324503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel.
    Yuen F; Wu S; Thirumalai A; Swerdloff RS; Page ST; Liu PY; Dart C; Wu H; Blithe DL; Sitruk-Ware R; Long J; Bai F; Hull L; Bremner WJ; Anawalt BD; Wang C
    Andrology; 2019 Mar; 7(2):235-243. PubMed ID: 30556332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial.
    Morgentaler A; McGettigan J; Xiang Q; Danoff TM; Gould EM
    Int J Impot Res; 2015; 27(2):41-5. PubMed ID: 25056809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism.
    Miller J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
    Endocr Pract; 2011; 17(4):574-83. PubMed ID: 21454244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of testosterone after percutaneous gel or buccal administration.
    Slater CC; Souter I; Zhang C; Guan C; Stanczyk FZ; Mishell DR
    Fertil Steril; 2001 Jul; 76(1):32-7. PubMed ID: 11438316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation.
    Rolf C; Knie U; Lemmnitz G; Nieschlag E
    Clin Endocrinol (Oxf); 2002 May; 56(5):637-41. PubMed ID: 12030915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haptic characterization of human skin in vivo in response to shower gels using a magnetic levitation device.
    Yardley R; Fan A; Masters J; Mascaro S
    Skin Res Technol; 2016 Feb; 22(1):115-27. PubMed ID: 26037842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abnormal testosterone levels in partners of patients using testosterone gels.
    Spielberg TE
    J Sex Med; 2005 Mar; 2(2):278. PubMed ID: 16422898
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.